Citius Pharmaceuticals, Inc. Share Price
NASDAQ: CTXR$0.55
+$0.55 (--%) Last updated on 30 Oct, 2026 | 19:41 ISTCitius Pharmaceuticals, Inc. Stock Performance
Citius Pharmaceuticals, Inc. Share Price Chart
$0.55$0.55
L
H
Citius Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Citius Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Citius Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $0.54 | $0.55 | -0.91% |
Sep 2026 | $0.58 | $0.55 | -10.26% |
Aug 2026 | $0.59 | $0.61 | +7.72% |
Jul 2026 | $0.62 | $0.57 | -2.40% |
Jun 2026 | $0.63 | $0.58 | -12.05% |
May 2026 | $0.69 | $0.66 | -3.07% |
Apr 2026 | $0.85 | $0.69 | -24.64% |
Mar 2026 | $0.72 | $0.91 | +24.01% |
Feb 2026 | $0.74 | $0.73 | -1.08% |
Jan 2026 | $0.79 | $0.74 | -3.14% |
Dec 2025 | $1.39 | $0.77 | -46.50% |
Nov 2025 | $1.58 | $1.43 | -8.33% |